Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.

Zhu S, Oremo JA, Li S, Zhen M, Tang Y, Du Y.

PLoS One. 2014 Mar 14;9(3):e91817. doi: 10.1371/journal.pone.0091817. eCollection 2014.

PMID:
24632829
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.

Park HS, Hong SK, Oh MM, Yoon CY, Jeong SJ, Byun SS, Cheon J, Lee SE, Moon du G.

Anticancer Res. 2014 Jul;34(7):3457-68.

PMID:
24982354
[PubMed - indexed for MEDLINE]
3.

Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.

Nelius T, Martinez-Marin D, Hirsch J, Miller B, Rinard K, Lopez J, de Riese W, Filleur S.

Cell Death Dis. 2014 May 8;5:e1210. doi: 10.1038/cddis.2014.180.

PMID:
24810046
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.

Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano MC, Lo Nigro C.

Anticancer Drugs. 2013 Feb;24(2):120-30. doi: 10.1097/CAD.0b013e328358d1dc.

PMID:
22990129
[PubMed - indexed for MEDLINE]
5.

Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.

Lin J, Wu H, Shi H, Pan W, Yu H, Zhu J.

PLoS One. 2013 Oct 14;8(10):e76169. doi: 10.1371/journal.pone.0076169. eCollection 2013.

PMID:
24155892
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.

PMID:
23954373
[PubMed - indexed for MEDLINE]
7.

Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.

Erten C, Karaca B, Kucukzeybek Y, Gorumlu G, Cengiz E, Gul MK, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA, Uslu R.

BJU Int. 2009 Jul;104(1):107-14. doi: 10.1111/j.1464-410X.2009.08340.x. Epub 2009 Feb 3.

PMID:
19191785
[PubMed - indexed for MEDLINE]
8.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A.

Future Oncol. 2013 Sep;9(9):1375-88. doi: 10.2217/fon.13.99.

PMID:
23980684
[PubMed - indexed for MEDLINE]
9.

MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.

Wei X, Zhou P, Lin X, Lin Y, Wu S, Diao P, Xie H, Xie K, Tang P.

Tumour Biol. 2014 Oct;35(10):10213-21. doi: 10.1007/s13277-014-2333-y. Epub 2014 Jul 17.

PMID:
25027405
[PubMed - indexed for MEDLINE]
10.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May 17.

PMID:
22608542
[PubMed - indexed for MEDLINE]
11.

Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model.

Dalezis P, Geromichalos GD, Trafalis DT, Pissimissis N, Panagiotopoulou D, Galaktidou G, Papageorgiou E, Papageorgiou A, Daifoti Z, Lymperi M, Koutsilieris M.

In Vivo. 2012 Jan-Feb;26(1):75-86.

PMID:
22210719
[PubMed - indexed for MEDLINE]
12.

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

Urol Oncol. 2013 Aug;31(6):776-86. doi: 10.1016/j.urolonc.2011.03.018. Epub 2011 Jul 27.

PMID:
21795074
[PubMed - indexed for MEDLINE]
13.

Treatment of liver cancer in mice by the intratumoral injection of an octreotide-based temperature‑sensitive gel.

Zhang L, Yu S, Duan Z, Wang Q, Tian G, Tian Y, Zhao W, Wang H, Zhang C, Guo S, Liu Q, He G, Bian T, Chang J, Jin X, Cui D.

Int J Mol Med. 2014 Jan;33(1):117-27. doi: 10.3892/ijmm.2013.1542. Epub 2013 Oct 30.

PMID:
24173662
[PubMed - indexed for MEDLINE]
14.

Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway.

Shaikh IA, Brown I, Schofield AC, Wahle KW, Heys SD.

Prostate. 2008 Nov 1;68(15):1635-46. doi: 10.1002/pros.20830.

PMID:
18668525
[PubMed - indexed for MEDLINE]
15.

Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines.

Zou Z, Xie L, Wei J, Yu L, Qian X, Chen J, Wang T, Liu B.

BMC Complement Altern Med. 2012 Apr 30;12:58. doi: 10.1186/1472-6882-12-58.

PMID:
22546220
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.

Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Sep;12(9):1829-36. doi: 10.1158/1535-7163.MCT-13-0208. Epub 2013 Jul 16.

PMID:
23861346
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.

Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP.

Cancer Res. 2004 Oct 15;64(20):7426-31.

PMID:
15492266
[PubMed - indexed for MEDLINE]
Free Article
18.

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.

Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M.

Endocr Relat Cancer. 2009 Jun;16(2):401-13. doi: 10.1677/ERC-08-0130. Epub 2009 Jan 19.

PMID:
19153211
[PubMed - indexed for MEDLINE]
Free Article
19.

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.

Prostate. 2010 Mar 1;70(4):433-42. doi: 10.1002/pros.21077.

PMID:
19866475
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk